#Shionogi

Apnimed Aims to Raise $160 Million in US IPO With Shionogi Backing

Shionogi-backed biotech Apnimed seeks to raise $160 million in a US IPO, highlighting investor appetite for sleep disorder treatments and cross-border healthcare…

Apnimed IPO Filing Aims to Fund Pivotal Sleep Apnea Drug Study

Apnimed, backed by Japanese drugmaker Shionogi, files IPO to raise capital for Phase 3 trial of oral sleep apnea therapy, targeting a…